Nospot0.01%+4%+0.05%

This triple-combination topical cream is indicated for the short-term treatment of moderate to severe melasma of the face, in patients also following measures for sun avoidance, including daily sunscreen use.

Important limitations of use:

• This product is not indicated for the maintenance treatment of melasma - it is used to bring melasma under control over a defined treatment period, not for indefinite ongoing use
• It has not been studied for hyperpigmentation conditions other than facial melasma, and should not be used for other types of skin discoloration without specific medical guidance
• Melasma commonly recurs after this cream is stopped, particularly with continued sun exposure or hormonal triggers (such as pregnancy or hormonal contraceptives); some patients are subsequently managed with other treatments once initial control is achieved

Each gram of cream contains fluocinolone acetonide 0.01% (0.1 mg, a corticosteroid), hydroquinone 4% (40 mg, a melanin synthesis inhibitor), and tretinoin 0.05% (0.5 mg, a retinoid), in a light yellow, hydrophilic cream base. The formulation also contains sodium metabisulfite, a sulfite preservative relevant to patients with sulfite sensitivity.

This is a triple-combination topical cream that pairs three different mechanisms to treat moderate to severe melasma (patchy facial skin discoloration) more effectively than any single ingredient alone: fluocinolone acetonide, a corticosteroid that reduces inflammation and irritation; hydroquinone, which inhibits melanin (skin pigment) production; and tretinoin, a retinoid that increases skin cell turnover and enhances penetration of the other two ingredients. It is applied once daily at night for a defined, short-term course under a doctor's supervision, always alongside strict daytime sun protection.

Therapeutic Class: Topical Depigmenting Agent (Triple Combination)

The precise mechanism by which the combination of these three active ingredients treats melasma has not been fully established, though each component's individual pharmacology is well characterized: fluocinolone acetonide suppresses local inflammatory mediators; hydroquinone inhibits the enzyme tyrosinase, reducing melanin production by melanocytes; and tretinoin accelerates epidermal cell turnover, which helps shed pigmented cells and improves penetration of the other two active ingredients. Systemic absorption of topical corticosteroids can occur and, with extensive or prolonged use, may produce reversible suppression of the hypothalamic-pituitary-adrenal axis.

• For topical use on the face only - not for oral, ophthalmic, or intravaginal use
• Wash the face and neck with a mild cleanser before application, then pat dry
• Apply a thin, even layer to the hyperpigmented areas and about half an inch of surrounding normal skin, rubbing in lightly
• Apply at least 30 minutes before bedtime, once daily, in the evening only
• Use a broad-spectrum sunscreen of SPF 30 or higher every day, and wear protective clothing; avoid direct sunlight exposure to the treated area
• Moisturizers and cosmetics may be used during the day
• Avoid medicated or abrasive soaps, cosmetics with a strong drying effect, products with high alcohol content, and other skin irritants or keratolytic agents while using this cream

The following should be considered when using this combination:

• Other topical products applied to the same skin area (such as other retinoids, exfoliants, medicated soaps, or products containing benzoyl peroxide): can increase skin irritation and dryness when combined; avoid using additional irritant skin products on treated areas.
• Photosensitizing medicines (such as certain antibiotics like tetracyclines, or other photosensitizing drugs): tretinoin already increases skin sensitivity to sunlight, and combining with other photosensitizing medicines may further increase this risk.
• Other topical corticosteroids used on the same or nearby skin areas: may increase the total corticosteroid exposure and associated risk of skin thinning or systemic absorption.

Common side effects

• Skin redness, peeling, dryness, burning sensation, and itching at the application site (mild to moderate irritation is expected with this combination and often improves with continued use)
• Acne-like breakouts (acneiform eruptions)

Less common effects (with topical corticosteroid use)

• Folliculitis, hypopigmentation of surrounding skin, perioral dermatitis, allergic contact dermatitis, secondary skin infection, skin thinning (atrophy), and stretch marks (striae) - more likely with prolonged use, higher-potency corticosteroids, or use under occlusive dressings

Serious effects (seek medical attention)

• Exogenous ochronosis: a gradual blue-black darkening of the treated skin, associated with hydroquinone; if this develops, discontinue use and consult a doctor - this has been reported more commonly, though not exclusively, in patients with darker skin
• Signs of hypothalamic-pituitary-adrenal axis suppression from systemic corticosteroid absorption (rare, mainly with extensive or prolonged use)
• Signs of a severe allergic reaction, including asthmatic symptoms in sulfite-sensitive patients: wheezing, difficulty breathing, widespread rash

Pregnancy

Tretinoin is considered highly teratogenic when given systemically, and although absorption from topical use is generally low, adequate reproductive safety data for this specific combination are not available; corticosteroids have also shown teratogenic effects in animal studies with systemic and, in some cases, dermal application. This product should not be used during pregnancy unless a doctor determines it is clearly necessary, and melasma commonly improves after delivery in any case, which may support deferring treatment.

Breastfeeding

It is not known whether topical application of this combination results in sufficient systemic absorption to produce detectable amounts of any of its three active ingredients in human milk. Because many drugs are excreted in human milk, caution should be exercised, and contact between a breastfeeding infant and treated skin should be avoided.

• Sun protection is essential - use a broad-spectrum sunscreen of SPF 30 or higher every day and avoid sun exposure to treated skin, since sunlight both worsens melasma and increases sensitivity to skin irritation from the retinoid component.
• Short-term use only - this product is not intended for maintenance treatment; use for the specific duration prescribed (commonly around 8 weeks) and stop once control is achieved, as directed by your doctor.
• Watch for ochronosis - a gradual blue-black darkening of the treated skin is a recognized risk with hydroquinone; report any unusual darkening to your doctor and discontinue use if it occurs.
• Sulfite sensitivity - this product contains sodium metabisulfite; patients with known sulfite sensitivity, more common among people with asthma, should use caution.
• Avoid other skin irritants, abrasive or medicated cleansers, high-alcohol-content products, and additional retinoid or exfoliating products on treated skin during therapy.
• The safety and efficacy of this cream in individuals with very dark skin (Fitzpatrick skin types V and VI) have not been specifically studied; excessive lightening resulting in an undesirable cosmetic effect cannot be excluded in patients with darker skin.

Topical overdose is unlikely with normal use on the face as directed, but excessive application, use over larger areas, or more frequent use than directed increases the risk of skin irritation and the systemic absorption-related risks described above. If accidentally ingested, seek medical advice, since systemic hydroquinone ingestion at high doses (single doses of several grams) has historically been associated with symptoms similar to phenol overdose, including tremors; oral ingestion of this product should be treated as a medical emergency in a child.

Store at controlled room temperature (generally 20-25°C, with excursions permitted between 15-30°C), away from direct light and heat, with the cap tightly closed after use. Keep out of reach of children.

• Darker skin types (Fitzpatrick V-VI): Safety and efficacy have not been specifically studied in this population; excessive bleaching or an undesirable cosmetic effect cannot be excluded.
• Children: Not established for use in the pediatric population, as melasma is primarily a condition of adult skin, often related to hormonal factors.
• Sulfite-sensitive patients, particularly those with asthma: Use with caution given the sodium metabisulfite content.

This combination is used for short-term treatment only, typically for around 8 weeks, and is discontinued once adequate control of the melasma is achieved, as directed by the prescribing doctor. It is explicitly not intended for ongoing maintenance treatment; some patients may be transitioned to other therapies once initial control is reached, since melasma commonly recurs after this cream is stopped, particularly with continued sun exposure.

Drug Class: Topical corticosteroid + melanin synthesis inhibitor (hydroquinone) + retinoid (tretinoin)

Fluocinolone acetonide reduces the local skin inflammation and irritation that hydroquinone and tretinoin can otherwise cause, improving tolerability of the combination. Hydroquinone blocks the pigment-producing enzyme tyrosinase, directly reducing new melanin formation in the treated skin. Tretinoin increases the rate of skin cell turnover, helping to shed pigmented surface cells and enhance the penetration and effectiveness of the hydroquinone. Together, these three complementary actions produce a greater lightening effect on melasma than any single ingredient used alone.

This combination is not established for use in children, as melasma is primarily a condition affecting adult skin, often triggered by hormonal factors, pregnancy, or sun exposure.